4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-24-000048
Chief Executive Officer sold 4,156 shares at $32.57 ($135,361)
- Chief Executive Officer acquired 8,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Goff Brian · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-03-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +8,500 | 57,936 | D | ||
| 2024-03-05 | Sale : show line 2 in the form 10b5-1 | −4,156 | $32.57 | $135,361 | 53,780 | D |
| Open-market sales · 4,156 sh · avg $32.57 · $135,361 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-03-01 | Grant or award : show line 3 in the form 10b5-1 Restricted stock units | +54,000 | 54,000 | D |
| 2024-03-01 | Grant or award : show line 4 in the form 10b5-1 Stock options (right to buy) | +195,500 | 195,500 | D |
| 2024-03-01 | Exercise or conversion : show line 5 in the form 10b5-1 Restricted stock units | −8,500 | 17,000 | D |
Loading xslF345X05/wk-form4_1709673014.xml…